Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $23.57 Average PT from Analysts

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have been given an average recommendation of “Moderate Buy” by the seven research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $23.57.

A number of research analysts recently weighed in on TEVA shares. UBS Group lowered their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Barclays dropped their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Finally, StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. This represents a 30.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. This represents a 29.15 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. CANADA LIFE ASSURANCE Co lifted its stake in shares of Teva Pharmaceutical Industries by 22.1% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 697,977 shares of the company’s stock valued at $15,371,000 after purchasing an additional 126,425 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Teva Pharmaceutical Industries by 87.8% in the 4th quarter. Marshall Wace LLP now owns 5,155,402 shares of the company’s stock worth $113,625,000 after acquiring an additional 2,410,420 shares during the last quarter. NewEdge Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 12.6% during the 4th quarter. NewEdge Advisors LLC now owns 35,482 shares of the company’s stock worth $782,000 after purchasing an additional 3,983 shares during the period. Gabelli Funds LLC increased its holdings in Teva Pharmaceutical Industries by 99.2% in the 4th quarter. Gabelli Funds LLC now owns 367,500 shares of the company’s stock valued at $8,100,000 after purchasing an additional 183,000 shares during the last quarter. Finally, Jump Financial LLC raised its position in Teva Pharmaceutical Industries by 128.0% in the fourth quarter. Jump Financial LLC now owns 487,103 shares of the company’s stock valued at $10,736,000 after purchasing an additional 273,493 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Up 1.5 %

Shares of TEVA stock opened at $16.59 on Friday. The stock has a 50 day simple moving average of $20.01 and a 200-day simple moving average of $18.50. Teva Pharmaceutical Industries has a 1-year low of $12.51 and a 1-year high of $22.80. The company has a market cap of $18.79 billion, a price-to-earnings ratio of -11.44, a PEG ratio of 1.39 and a beta of 0.71. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.61.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts expect that Teva Pharmaceutical Industries will post 2.62 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.